Chronic lymphocytic leukemia (CLL) accounts for about one-fourth of all new leukemia cases and diagnosis typically comes from routine bloodwork. While most cases result in a watch-and-wait strategy, understanding the underpinnings of this disease has helped advance CLL care, research and treatment.
Guest: John Allan, MD, hematologist and medical oncologist specializing in the treatment and care of chronic lymphocytic leukemia patients at Weill Cornell Medicine and NewYork-Presbyterian Hospital.
Host: John Leonard, MD, a leading hematologist and medical oncologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital.
Chronic lymphocytic leukemia (CLL) accounts for about one-fourth of all new leukemia cases and diagnosis typically comes from routine bloodwork. While most cases result in a watch-and-wait strategy, understanding the underpinnings of this disease has helped advance CLL care, research and treatment.